Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Bandwidth Inc (BAND) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Bandwidth Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.99 (market cap $4.49B), while Bandwidth Inc trades at $71.14 (market cap $1.94B). The key difference: ACADIA Pharmaceuticals Inc. is far larger — about 2.3× Bandwidth Inc's market cap, and Bandwidth Inc is trading nearer its 52-week high, ACADIA Pharmaceuticals Inc. nearer its low. Which is the better fit depends on your goals.
| ACAD | BAND | |
|---|---|---|
Market Cap | $4.49B | $1.94B |
Sector | Health | Technology |
52-Week High | $28.06 | $73.19 |
52-Week Low | $20.06 | $12.82 |
Enterprise Value | $3.69B | $2.32B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Bandwidth (BAND) trades at $60.67, down 1.51% on the day, with a bullish technical signal supported by moving averages. The company reported Q1 2026 EPS of $0.38, beating expectations, but maintains negative net income margins. Recent news highlights the launch of the AI-driven Bandwidth Build platform and a $275 million convertible notes offering, fueling growth optimism in cloud communications.
The outlook is mixed: strong analyst buy consensus (75%) and AI expansion offer upside, but profitability concerns and high valuation multiples pose risks. Revenue growth is projected to improve, yet negative ROE and net income require monitoring. The stock's momentum depends on execution of AI initiatives and path to sustained profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Bandwidth Inc
Bandwidth is a global communications software company. Its CPaaS platform allows enterprises to embed voice, messaging, and 911 emergency services directly into their software applications via robust APIs.
Read more on BAND →
